Medicenna completes enrollment in MDNA11 Phase 1/2 cancer study
Tweet Send to a Friend
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced it has completed enrollment in its global Phase 1/2 ABILITY-1 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




